Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

Fig. 1

Treatment schedule. All patients were scheduled to receive conventional radio-chemotherapy with up to 12 cycles of adjuvant temozolomide or until disease progression. The first intradermal DCs administrations were scheduled prior to radiotherapy, and the second 3 weeks after radiotherapy. This was followed by two monthly, four bi-monthly, and subsequent quarterly administrations until the end of all available doses. During adjuvant TMZ treatment, DC were administered on day 21 of the corresponding cycle. Vaccines were administered intradermally

Back to article page